The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).
Iconic One Theme | Powered by Wordpress
The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).